Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Lyell Immunopharma, Inc.

LYEL · Nasdaq · CIK 0001806952 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

20 Form 4 transaction lines observed in the same window
16 sales · 4 option, withholding, award, gift or other lines

Last qualifying purchase2026-03-06 · ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC · $12.5M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Innovative Cellular Therapeutics Holdings LtdTenPercentOwner
○○▼▼○○
Seely LynnPresident and CEO
▼▼▼
Lee Gary K.Chief Scientific Officer
▼▼▼
Hill Stephen J.Chief Operating Officer
▼▼▼
Shook DavidChief Medical Officer
▼▼
Bulis Veronica SanchezVP, Corporate Controller
▼▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-03-06 · ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLC.

Recent Form 4 activity

2Purchases
29Sales
8Other Form 4 lines
34SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING16 sale line(s) · context only
OTHER4 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,263,394
Previous report
1,187,902
Avg daily volume
170,775
Days to cover
7.4

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-03-06ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTPurchase (P)Common Stock488,090USD 25.61USD 12,499,985SEC filing ↗
2026-03-06ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLCPurchase (P)Common Stock488,090USD 25.61USD 12,499,985SEC filing ↗
2025-03-31BRAWLEY OTIS WPurchase (P)Common Stock35,640USD 0.56USD 19,958SEC filing ↗
2025-03-21Ramachandra SumantPurchase (P)Common Stock200,000USD 0.58USD 116,000SEC filing ↗
2025-03-17Newton Charles W.Purchase (P)Common Stock200,000USD 0.56USD 112,000SEC filing ↗
2025-03-14Seely LynnPurchase (P)Common Stock175,000USD 0.61USD 106,750SEC filing ↗
2025-03-14Klausner RichardPurchase (P)Common Stock158,000USD 0.60USD 94,800SEC filing ↗
2021-06-21FRIEDMAN CATHYPurchase (P)Common Stock17,648USD 17.00USD 300,016SEC filing ↗

Form 4 evidence

39 transaction lines in the latest 365-day window; 84 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Aguirre Jarrad MattieuSale (S)Common Stock422USD 8.63USD 3,642SEC filing ↗
2026-09-10Shook DavidSale (S)Common Stock500USD 12.70USD 6,350SEC filing ↗
2026-08-21Seely LynnSale (S)Common Stock9,589USD 15.54USD 149,013SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Aguirre Jarrad MattieuSale (S)Common Stock422USD 8.63USD 3,642SEC filing ↗
2026-09-10Shook DavidSale (S)Common Stock500USD 12.70USD 6,350SEC filing ↗
2026-08-21Seely LynnSale (S)Common Stock9,589USD 15.54USD 149,013SEC filing ↗
2026-08-21Lee Gary K.Sale (S)Common Stock1,457USD 15.54USD 22,642SEC filing ↗
2026-08-21Hill Stephen J.Sale (S)Common Stock989USD 15.54USD 15,369SEC filing ↗
2026-08-10Seely LynnSale (S)Common Stock390USD 14.34USD 5,593SEC filing ↗
2026-08-10Lee Gary K.Sale (S)Common Stock131USD 14.34USD 1,879SEC filing ↗
2026-08-10Hill Stephen J.Sale (S)Common Stock89USD 14.34USD 1,276SEC filing ↗
2026-08-10Bulis Veronica SanchezSale (S)Common Stock621USD 14.34USD 8,905SEC filing ↗
2026-07-27Innovative Cellular Therapeutics Holdings LtdJ (J)Common Stock44,000USD 0.00USD 0SEC filing ↗
2026-07-27Innovative Cellular Therapeutics Holdings LtdJ (J)Common Stock38,500USD 0.00USD 0SEC filing ↗
2026-07-17Innovative Cellular Therapeutics Holdings LtdSale (S)Common Stock10USD 13.70USD 137SEC filing ↗
2026-07-16Innovative Cellular Therapeutics Holdings LtdSale (S)Common Stock10USD 13.73USD 137SEC filing ↗
2026-06-29Innovative Cellular Therapeutics Holdings LtdJ (J)Common Stock76,000USD 0.00USD 0SEC filing ↗
2026-06-15Innovative Cellular Therapeutics Holdings LtdJ (J)Common Stock66,500USD 0.00USD 0SEC filing ↗
2026-06-10Shook DavidSale (S)Common Stock1,977USD 12.64USD 24,989SEC filing ↗
2026-05-11Seely LynnSale (S)Common Stock388USD 18.91USD 7,337SEC filing ↗
2026-05-11Lee Gary K.Sale (S)Common Stock130USD 18.92USD 2,460SEC filing ↗
2026-05-11Hill Stephen J.Sale (S)Common Stock89USD 18.92USD 1,684SEC filing ↗
2026-05-11Bulis Veronica SanchezSale (S)Common Stock217USD 18.91USD 4,103SEC filing ↗
2026-03-06ARCH Venture Fund XIII, L.P.; ARCH Venture Partners XIII, L.P.; ARCH Venture Partners XIII, LLC; BERNS PAUL L; BYBEE CLINTON; Burow Kristina; CRANDELL KEITH; GILLIS STEVEN; NELSEN ROBERTPurchase (P)Common Stock488,090USD 25.61USD 12,499,985SEC filing ↗
2026-03-06ARCH Venture Fund IX Overage, L.P.; ARCH Venture Fund IX, L.P.; ARCH Venture Partners IX Overage, L.P.; ARCH Venture Partners IX, L.P.; ARCH Venture Partners IX, LLCPurchase (P)Common Stock488,090USD 25.61USD 12,499,985SEC filing ↗
2026-02-11Seely LynnSale (S)Common Stock7,455USD 23.39USD 174,372SEC filing ↗
2026-02-11Lee Gary K.Sale (S)Common Stock1,671USD 23.39USD 39,085SEC filing ↗
2026-02-11Hill Stephen J.Sale (S)Common Stock1,236USD 23.39USD 28,910SEC filing ↗
2026-02-10Seely LynnSale (S)Common Stock438USD 23.12USD 10,127SEC filing ↗
2026-02-10Lee Gary K.Sale (S)Common Stock147USD 23.12USD 3,399SEC filing ↗
2026-02-10Hill Stephen J.Sale (S)Common Stock109USD 23.12USD 2,520SEC filing ↗
2026-02-10Bulis Veronica SanchezSale (S)Common Stock254USD 23.12USD 5,872SEC filing ↗
2026-02-10Bulis Veronica SanchezAward / grant (A)Common Stock8,750USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerLYEL
CIK0001806952
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history84 transaction lines from 2021-06-21 to 2026-10-12
8 P purchase lines · 43 S sale lines · 33 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.